Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Conducts First Centralized Purchasing For Medical Consumables

This article was originally published in PharmAsia News

Executive Summary

China's Ministry of Health has successfully conducted the 2008 national centralized purchasing of high-value medical consumables, at an average 10 percent lower rate. The first such exercise to supply medical institutions nationwide, the products purchased are classified into four categories: cardiac pacemaker, electrophysiology, cardiac intervention and peripheral vascular intervention (neurological intervention). MOH will publicize candidates' product catalogs and pricing in the near future. Non-profit medical institutions across the country may purchase these items; in principle, they should not buy similar products outside the catalog. Experts point out that the centralized purchasing can unify pricing of different regions in China, paving the way toward formulating standardized charging for medical care services. (Click here for more - Chinese Language)

You may also be interested in...

China MOH Releases 2008 Catalogs Of Centralized Purchasing For Medical Consumables

China's Ministry of Health has published the 2008 candidates' product catalogs for the national centralized purchasing of high-value medical consumables (PharmAsia News, Aug. 11, 2008), with the details posted on its International Communication and Cooperation Center website. MOH requires all regions to execute the purchase from Oct.1, within a one-year purchasing cycle. China's urban health care institutions' expenditure on medical consumables increased at an annual rate of 22.4 percent from RMB 9.693 billion ($1.417 billion) to RMB 39.831 billion ($5.825 billion) between 2000 and 2007, far exceeding drug expenses. Experts reveal that the government plans to include all medical devices into centralized purchasing by 2010. The country's increased investment of RMB 150 billion in public health and government purchase, with priority for local brands, will boost the domestic medical devices industry. (Click here for more - Chinese Language)

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts